Recombinant Human TNF RI Protein (C-Fc)

Beta LifeScience SKU/CAT #: BL-0150NP
BL-0150NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
BL-0150NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Recombinant Human TNF RI Protein (C-Fc)

Beta LifeScience SKU/CAT #: BL-0150NP
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Tumor Necrosis Factor Receptor I is produced by our Mammalian expression system and the target gene encoding Leu30-Thr211 is expressed with a human IgG1 Fc tag at the C-terminus.
Accession P19438
Synonym Tumor necrosis factor receptor superfamily member 1A;TNFRSF1A;Tumor necrosis factor receptor 1; TNF-R1; TNF-RI; p55; p60; CD120a; TNFAR; TNFR1
Gene Background Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) is a member of the tumor necrosis factor receptor superfamily. TNFRSF1A is one of the major receptors for the tumor necrosis factor-alpha. It can activate the transcription factor NF-κB, mediate apoptosis, and function as a regulator of inflammation. Antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRADD and TRAF2 have been shown to interact with this receptor, and thus play regulatory roles in the signal transduction mediated by the receptor. Germline mutations of the extracellular domains of this receptor were found to be associated with the human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS) or periodic fever syndrome.
Molecular Mass 47.2 KDa
Apmol Mass 60 KDa, reducing conditions
Formulation Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Endotoxin Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity Not tested
Reconstitution Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage For Research Use Only

Target Details

Target Function Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase.
Subcellular Location Cell membrane; Single-pass type I membrane protein. Golgi apparatus membrane; Single-pass type I membrane protein. Secreted. Note=A secreted form is produced through proteolytic processing.; [Isoform 4]: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.
Database References
Associated Diseases Familial hibernian fever (FHF); Multiple sclerosis 5 (MS5)

Gene Functions References

  1. Elevated TNFRs levels were associated with the risk of cardiovascular and/or all-cause mortality independent of all relevant covariates in patients undergoing haemodialysis PMID: 28256549
  2. It has been demonstrated that the molecular genetic marker +36G TNFR1 (OR=1,25) is involved in the formation Essential Hypertension in individuals with Metabolic Syndrome. PMID: 30289218
  3. Due to the fact that the mutation was not inherited from the parents, it was likely that R426L was a de novo and novel mutation in the TNFRSF1A gene, which can trigger TRAPS or TRAPS-like symptoms. PMID: 27793577
  4. this study evaluated TNFR1 -609G/T polymorphisms association with RA susceptibility in a sample of Mexican patients. Our results suggest that the TNFR1 -609G/T polymorphisms are not associated with RA susceptibility in a sample of Mexican patients. PMID: 29404828
  5. Polymorphisms in the TNFR1 gene may have an impact on the symptomatology of schizophrenia in men. rs4149577 and rs1860545 SNPs were associated with the intensity of the Positive and Negative Syndrome Scale (PANSS) excitement symptoms in men, which may contribute to the risk of violent behavior. PMID: 29317797
  6. Polymorphism of Promoter Region of TNFRSF1A Gene is associated with Radiotherapy Induced Oral Mucositis in Head and Neck Cancer. PMID: 28401452
  7. five single nucleotide polymorphisms in the TNFRSF1A gene are not associated with autoimmune thyroid diseases in the Chinese Han population, but rs4149570 shows a weak association with Hashimoto's thyroiditis after adjusting for gender and age. PMID: 29401539
  8. Genotype rs767455 was associated with the susceptibility of ankylosing spondylitis(AS), G allele of rs767455 exhibited an association with the risk of developing AS. Only rs1061622 was significantly associated with long-term efficacy of etanercept. The results suggest that TNFRSF1A and TNFRSF1B polymorphisms were associated with susceptibility, severity, and the long-term therapeutic efficacy of etanercept of AS patients. PMID: 30075559
  9. RACK1 associates with MOAP-1 via electrostatic associations similar to those observed between MOAP-1/RASSF1A and MOAP-1/TNF-R1. These events illustrate the complex nature of MOAP-1 regulation and characterizes the important role of the scaffolding protein, RACK1, in influencing MOAP-1 biology. PMID: 29470995
  10. serum level did not decrease significantly after tonsillectomy with steroid pulse therapy in IgA nephropathy PMID: 28389814
  11. The TNFRSF1A c.625+10 G allele was associated with late response to anti-TNFalpha therapy but TNFRSF1A gene SNPs is not associated with spondyloarthritis. PMID: 29579081
  12. TNFR1 is associated longitudinally with kidney function decline but not with myocardial infarct, heart failure, or mortality risk after adjustment PMID: 28601698
  13. One third of our childhood MS patients had a heterozygous mutation in the TNFRSF1A and/or MEFV gene. This proportion by far exceeds the number of mutations expected and was higher than in adult MS patients, suggesting that these mutations might contribute to the pathogenesis of childhood MS. PMID: 28927886
  14. Studied the association of NLR family pyrin domain containing 3 (NLRP3) and tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) polymorphisms and haplotypes in patients with ankylosing spondylitis (AS) and treatment response to etanercept. PMID: 28116820
  15. Investigations of underlying molecular mechanisms of TNFR1 signaling showed that PDF affects TNFR1 signaling at the proapoptotic signaling pathway by upregulation of IkappaBalpha and downregulation of cFLIPL. PMID: 28096440
  16. Case Report: tumor necrosis factor receptor-associated periodic syndrome due to the R92Q TNFRSF1A variant associated with recurrent pericarditis and cardiac tamponade. PMID: 27990755
  17. Serum TNFR1 is a biomarker for patients with chronic kidney disease. PMID: 28667032
  18. This study demonstrated that TNFR1 expression levels are related to major depressive disorder and conjunctly mediate the effect of childhood maltreatment history on the risk of developing major depressive disorder. PMID: 28384542
  19. SNP (36A>G) is strong risk factor for odontogenic keratocystic tumor PMID: 28199753
  20. Data suggest that Fas and TNFR1 are involved in glaucoma mechanisms in cornea; pro-apoptotic effect of anti-glaucoma medication clonidine on corneal epithelial cells triggers Fas/TNFR1-mediated, mitochondria-dependent signaling pathway. (Fas = Fas cell surface death receptor ; TNFR1 = TNF receptor superfamily member 1A) PMID: 28115640
  21. These results indicate that TNFRI-Fc and hHO-1 overexpression may apparently induce free iron in the liver and exert oxidative stress by enhancing reactive oxygen species production and block normal postneonatal liver metabolism. PMID: 28503569
  22. Data suggest that elevated serum levels of soluble TNF receptors, especially sTNFR1, are associated with loss of kidney function in Hispanic patients with diabetes type 2 in Colombia. PMID: 27068267
  23. Case Report: heterozygous missense variants in TNFRSF1A identified in family members with familial Mediterranean fever. PMID: 29148404
  24. Case Report: autoinflammatory syndrome with relapsing aseptic neutrophilic meningitis and chronic myelitis associated with MEFV/TNFRSF1A mutations. PMID: 28134085
  25. In this article we will review the role of ubiquitination and proteolysis in these diverse events focusing on our own contributions to the lysosomal apoptotic pathway linked to the subcellular compartmentalization of TNF-R1 PMID: 28765050
  26. Coadministration of either ATROSAB or EHD2-scTNFR2 into the magnocellular nucleus basalis significantly protected cholinergic neurons and their cortical projections against cell death, and reverted the neurodegeneration-associated memory impairment in a passive avoidance paradigm. Simultaneous blocking of TNFR1 and TNFR2 signaling, however, abrogated the therapeutic effect PMID: 27791020
  27. Data show that interleukin-2 receptor alpha, tumor necrosis factor receptor 1, serum STimulation-2 (IL1RL1 gene product), and regenerating islet-derived 3-alpha were significantly associated with non-relapse mortality. PMID: 28126963
  28. Report of a severe case of TRAPS associated with a novel mutation, Thr90Pro, in the TNFRSF1A gene in an infant and several family members. PMID: 28427379
  29. atopic dermatits patients had increased TNFR1 expression on immune cells PMID: 29212072
  30. Elevated level of soluble tumor necrosis factor receptors 1 and lower level of leptin are associated with higher developmental outcomes in infants between the ages of 6 and 24 months. PMID: 28238825
  31. The highest levels of TNFR1 are independently associated with progression of renal disease and death in type 2 diabetic nephropathy. PMID: 27003829
  32. High plasma levels of TNFR1 and TNFR2 were associated with incident intracerebral hemorrhage. PMID: 28830973
  33. Renal clear cell carcinoma cells cells express increased amounts of RIPK1 and RIPK3 and are poised to undergo necroptosis in response to TNFR1 signaling. PMID: 27362805
  34. TRIM28 acts as a central factor in controlling endothelial inflammatory responses and angiogenic activities by retaining expression of TNFR-1 and -2 and VEGF receptor 2 in endothelial cells PMID: 28159803
  35. a specific link between the penetrance of the TNFRSF1A mutation and the observed T cell phenotype, is reported. PMID: 26598380
  36. Collectively, this study provides more insights into RELT expression, RELT family member function, and the mechanism of RELT-induced death. PMID: 28688764
  37. Burkholderia cenocepacia BcaA binds to tumor necrosis factor receptor 1. PMID: 27684048
  38. TNFRSF1A variants were identified in 10 tumor necrosis factor receptor-associated periodic syndrome patients from 10 independent families. The T61I variant was found in patients, while the V136M and S321I variants were found in 1 patient each. All the patients were heterozygous for the variants. Among the healthy controls, 7 of 363 individuals were heterozygous for the T61I variant. PMID: 27332769
  39. Voxel-based morphometry was used to analyse the associations between TNFRSF1A (rs4149576 and rs4149577) and grey matter structure. Highly significant genotypic associations with striatal volume but not the hippocampus were seen. Specifically, for rs4149576, G homozygotes were associated with reduced caudate nucleus volumes relative to A homozygotes and heterozygotes. Reduced caudate volumes were observed in C homozygotes PMID: 27528091
  40. Circulating TNFR1 and 2 were shown to be associated with cardiovascular disease, independent of age, sex, inflammatory markers, and other cardiovascular disease risk factors, in the chronic kidney disease patients PMID: 28489742
  41. Infection with C. trachomatis disturbs TNFR1 signalling specifically at the level of receptor internalization. PMID: 27062399
  42. Data suggest that TRAF2 (TNF receptor-associated factor 2) negatively regulates (1) TNFR1- (tumor necrosis factor binding protein 1)-induced apoptosis, (2) TNFR2- (tumor necrosis factor receptor type 2)-induced non-canonical NFkappaB signaling, and (3) TNF- (tumor necrosis factor)-induced necroptosis. [REVIEW] PMID: 26993379
  43. Our analysis showed that the TNFR1 rs2234649 polymorphism does not increase ankylosing spondylitis risk. In conclusion, the TNFR1 gene polymorphism tested does not appear to be useful for assessing predisposition to ankylosing spondylitis. PMID: 28363009
  44. elevated serum level associated with heart failure risk in type 2 diabetes mellitus patients PMID: 28367848
  45. The data demonstrate a novel and unexpected function of BIG1 that regulates TNFR1 signaling by targeting TRAF2. PMID: 27834853
  46. Data indicate that plasma concentrations of TNFR1 and TNFR2 are elevated in pediatric lupus nephritis. PMID: 26854079
  47. TNFR1 is the major pro-inflammatory mediator of TNF-alpha in fibroblast-like synoviocytes (FLS), whereas TNFR2, may act as an immunosuppressor in FLS for the prevention of overwhelming inflammatory reactions. PMID: 28150360
  48. Results suggest that miR-29a is an important regulator of tumor necrosis factor receptor 1 expression in breast cancer and functions as a tumor suppressor by targeting tumor necrosis factor receptor 1 to influence the growth of MCF-7 cell. PMID: 28222663
  49. Serum sTNFR1 and sTNFR2 are associated with obese girls but not obese boys, thereby suggesting that serum sTNFRs in early childhood obesity may be sex related. PMID: 27040725
  50. SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors have roles in squamous cell cervical cancer PMID: 26289850

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed